Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) EBIT : ¥709 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Sunshine Guojian Pharmaceutical (Shanghai) Co EBIT?

Sunshine Guojian Pharmaceutical (Shanghai) Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was ¥463 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was ¥709 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized ROC % for the quarter that ended in Dec. 2024 was 2.06%. Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 78.10%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sunshine Guojian Pharmaceutical (Shanghai) Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 5.02%.

Sunshine Guojian Pharmaceutical (Shanghai) Co EBIT Historical Data

The historical data trend for Sunshine Guojian Pharmaceutical (Shanghai) Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Guojian Pharmaceutical (Shanghai) Co EBIT Chart

Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data

Trend

Dec12

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-217.88

-73.31

30.27

312.04

708.83

Sunshine Guojian Pharmaceutical (Shanghai) Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT	Get a 7-Day Free Trial															141.68	100.17	38.83	106.67	463.17

Competitive Comparison of Sunshine Guojian Pharmaceutical (Shanghai) Co's EBIT

For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Sunshine Guojian Pharmaceutical (Shanghai) Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥709 Mil.

Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	88.528 * ( 1 - -1.24% )	/	( (4341.1	+	4348.311)	/ 2 )
=	89.6257472	/	4344.7055
=	2.06 %

where

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5917.949	-	258.758	-	( 1318.091	-	max(0, 760.601	-	2670.397	+	1318.091	))
=	4341.1

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5965.027	-	246.685	-	( 1370.031	-	max(0, 316.908	-	2660.033	+	1370.031	))
=	4348.311

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1852.688	/	( ( (1549.862 + max(636.718, 0))	+	(1538.941 + max(1018.875, 0)) )	/	2 )
=	1852.688	/	( ( 2186.58	+	2557.816 )	/	2 )
=	1852.688	/	2372.198
=	78.10 %

where Working Capital is:

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(236.882	+	203.544	+	906.868)	-	(258.758	+	0	+	451.818)
=	636.718

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(142.933	+	229.598	+	913.23)	-	(246.685	+	0	+	20.201)
=	1018.875

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sunshine Guojian Pharmaceutical (Shanghai) Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2024 )
	=	708.831	/	14118.214
	=	5.02 %

Sunshine Guojian Pharmaceutical (Shanghai) Co EBIT Related Terms

Thank you for viewing the detailed overview of Sunshine Guojian Pharmaceutical (Shanghai) Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd (SHSE:688336) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.399 Libing Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203

Website

https://www.3s-guojian.com

Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.

Executives

Weng Zhi Bing	Core technical personnel
Huang Hao Min	Core technical personnel

Sunshine Guojian Pharmaceutical (Shanghai) Co Headlines

No Headlines